Exelixis Inc.

S&P 500

EXEL/Healthcare · Biotechnology/NASDAQ

Stock Price

$53.23

Stock Price$53.23P/E17.0MCap12.9BLast update: Jun 26, 2026 at 06:56

Dividend Safety Rating

N/A/ 100

Dividend Safety Rating

EXEL does not currently pay a dividend. The Dividend Safety Rating is not applicable for non-dividend stocks.

About Exelixis Inc.

Exelixis Inc. is an oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. Its lead product, CABOMETYX tablets (cabozantinib), treats advanced renal cell carcinoma in patients following prior anti-angiogenic therapy and supports expansion into indications like neuroendocrine tumors. COMETRIQ capsules (cabozantinib) address progressive, metastatic medullary thyroid cancer. The company also markets COTELLIC (cobimetinib) and advances a pipeline including zanzalintinib, evaluated in trials such as STELLAR-303 for metastatic colorectal cancer in combination with immune checkpoint inhibitors. Exelixis leverages expertise in chemistry, biology, and strategic partnerships to develop small molecules, bispecific antibodies, antibody-drug conjugates, and other innovative anti-cancer therapies. These efforts target tyrosine kinases like MET, AXL, RET, and VEGF receptors, aiming to inhibit cancer growth and metastasis. Founded in 1994 and headquartered in Alameda, California, Exelixis plays a vital role in oncology by challenging treatment norms and broadening therapeutic options for patients worldwide.

Dividend Overview

Dividend Yield

0.00%

Annual Dividend

$0.00

Frequency

N/A

Payout Ratio

0.00%

FCF Payout Ratio

0.00%

52-Week Range

$33.76 - $53.93

Earnings & Profitability

EXEL earnings per share and net profit margin

Key Dates

Next Ex-Dividend Date

—

Next Payment Date

—

Dividend Growth

3-Year Dividend CAGR

N/A

5-Year Dividend CAGR

N/A

10-Year Dividend CAGR

N/A

3-Year Total Growth

N/A

5-Year Total Growth

N/A

10-Year Total Growth

N/A

Income Calculator

EXEL Dividend Calculator

Number of Shares

Total Investment

$5,323.00

Annual Income

$0.00

Quarterly Income

$0.00

Monthly Income

$0.00

Frequently Asked Questions

What is EXEL's current dividend yield?

Exelixis Inc. (EXEL) currently has a dividend yield of 0.00%, based on a stock price of $53.23 and an annual dividend of $0.00.

When is EXEL's next dividend payment date?

EXEL's next ex-dividend date is — and the next payment date is —. You must own the stock before the ex-dividend date to receive the upcoming payment.

How much does EXEL pay in dividends per year?

Exelixis Inc. pays dividends unknown. Annual dividend data is not yet available.

Has EXEL been increasing its dividend?

Exelixis Inc. has grown its dividend at a 5-year CAGR of —.

Is EXEL's dividend safe?

Exelixis Inc. has a payout ratio of 0.00%. Its free cash flow payout ratio is 0.00%. A payout ratio below 60% is generally considered sustainable.

How is EXEL's Dividend Safety Rating calculated?

The Dividend Safety Rating evaluates Exelixis Inc.'s dividend sustainability across four categories: Payout & Coverage (30%), Balance Sheet (20%), Profitability (20%), and Dividend Track Record (30%). Each metric is rated from "Very Safe" to "Danger" based on industry-standard thresholds, with sector-specific adjustments for healthcare companies. The overall score ranges from 0 to 100.

Want to understand how we rate dividend safety? Read our full methodology

Track EXEL Dividends with OnlyDividends

What will EXEL actually pay you after taxes? Track every payout, get notified on payment dates, and stop guessing.

This page is not investment advice. The content is for informational purposes only and should not be construed as a recommendation to buy, sell, or hold any security. Always do your own research and consult a qualified financial advisor before making investment decisions.

Financial data, including dividend history, earnings, balance sheet metrics, and the Dividend Safety Rating, is provided for informational purposes only. Data may be delayed or differ from official filings. Past performance does not guarantee future results. Always verify with official sources before making investment decisions.

Market data provided by Twelve Data.